Verified HPLC purities (≥98%–99.5%), validated batch traceability, and rapid global cold-chain fulfillment.
SS-31 (also designated Szeto-Schiller peptide 31, Elamipretide, or Bendavia) represents a paradigm shift in mitochondrial pharmacology. Unlike conventional antioxidants that merely scavenge reactive oxygen species (ROS) in bulk cellular water after oxidative collateral damage has already occurred, SS-31 targets the root origin of electron leakage within the inner mitochondrial membrane (IMM).
SS-31 is an aromatic-cationic tetrapeptide with the primary structural formula: H-D-Arg-Dmt-Lys-Phe-NH2 (where Dmt represents 2',6'-dimethyltyrosine, Chemical Formula: C32H49N9O5, CAS Number: 736992-21-5). Its design incorporates alternating aromatic residues and basic amino acids with a net +3 charge at physiological pH 7.4. Crucially, the peptide rapidly penetrates cellular and mitochondrial membranes independently of mitochondrial membrane potential (ΔΨm) through a non-endocytic, carrier-free partition mechanism, accumulating >1,000-fold within the IMM.
SS-31 engages in stereospecific electrostatic and hydrophobic interactions with cardiolipin, the unique tetra-acyl phospholipid localized exclusively on the IMM. By docking into cardiolipin's microdomains, SS-31 prevents cardiolipin peroxidative degradation, maintaining inner membrane curvature and cristae architecture.
By protecting cardiolipin, SS-31 directly optimizes the functional assembly of Respiratory Supercomplexes (respirasomes) involving Complexes I, III, and IV. It accelerates cytochrome c electron shuttling, thereby preventing early electron leakage to molecular oxygen and halting pathogenic superoxide (O2•-) generation at source.
Ischemia-reperfusion injury and systemic metabolic stress cause calcium overload and the pathological opening of the Mitochondrial Permeability Transition Pore (mPTP). SS-31 desensitizes mPTP activation, stopping mitochondrial matrix swelling, membrane rupture, and apoptotic release of cytochrome c.
Under hypoxic or aging conditions, Complex V (ATP synthase) loses structural cohesion due to cardiolipin loss. SS-31 preserves proton-motive force coupling across the IMM, yielding a 30%–50% recovery in cellular ATP generation capacity without elevating cellular oxygen consumption.
From rare genetic mitochondrial diseases to pervasive metabolic, cardiovascular, and dermal indications, industrial formulation scientists utilize pharmaceutical-grade SS-31 for target validation, preclinical IND programs, and commercial API sourcing.
Renal proximal tubular epithelial cells possess the highest mitochondrial density outside cardiomyocytes. In acute ischemic AKI and contrast-induced nephropathy models, SS-31 administration attenuates tubular cell brush-border loss, restores medullary microcirculation, and prevents transition to chronic fibrotic kidney disease (CKD).
Barth Syndrome is characterized by genetic defects in the tafazzin (TAZ) gene responsible for cardiolipin remodeling, causing profound muscle weakness and dilated cardiomyopathy. SS-31 structurally compensates for defective monolysocardiolipin conversion, restoring mitochondrial bioenergetics in striated muscle tissues.
In post-infarction left ventricular remodeling and age-dependent diastolic dysfunction, myocardial stiffness is driven by hyper-oxidized titin and cardiomyocyte energetic crisis. SS-31 preserves myocardial compliance, reduces left ventricular end-diastolic pressure, and accelerates hemodynamic recovery.
Neurons depend critically on axonal mitochondrial transport. In preclinical models of Parkinson's, Alzheimer's, and Amyotrophic Lateral Sclerosis (ALS), SS-31 protects Complex I from toxic oligomer insult, suppresses microglial neuroinflammation, and maintains long-term potentiation (LTP) in hippocampal circuits.
Retinal pigment epithelium (RPE) cells endure lifetime photo-oxidative stress. Formulated as topical ocular drops or intravitreal micro-depots, SS-31 shields RPE cells from lipid hydroperoxide cytotoxicity and prevents retinal ganglion cell (RGC) apoptosis under elevated intraocular pressure.
Skin chronosenescence and photo-aging are intimately linked to mitochondrial DNA (mtDNA) 4977-bp common deletions in dermal fibroblasts. Skincare innovators formulate cosmetic-grade SS-31 to rescue procollagen-I secretion, downregulate MMP-1 collagenase expression, and restore youthful elasticity.
How Thinheal's dedicated peptide synthesis base in Heda Medicine Valley, Hangzhou, provides global pharmaceutical purchasers with scalable, cost-resilient, and disruption-proof commercial supply continuity.
Purpose-built peptide API and CDMO facility in Hangzhou.
Core management leadership from tier-1 biopharma synthesis plants.
Industrial-scale SPPS reactors ensuring bulk supply stability.
Strict single-impurity thresholds (≤0.1% or ≤0.5% specified).
Thinheal procures bulk protected amino acids (Fmoc-D-Arg(Pbf)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH) and specialty unnatural residues (Fmoc-Dmt-OH) through long-term strategic joint-venture suppliers located in Zhejiang and Jiangsu chemical clusters. This eliminates supply vulnerabilities, raw material spikes, and multi-month delays common in decentralized synthesis networks.
Our workshop houses multiple 500L, 1000L, and 2000L automated solid-phase synthesis reactors linked with DAC (Dynamic Axial Compression) prep-HPLC columns (300mm to 600mm ID). This industrial configuration allows continuous campaign runs producing 50kg to 200kg single-batch lots of SS-31 with reproducible diastereomeric purity, minimal TFA retention, and uniform crystalline structure.
Through systematic solvent recovery systems (over 85% DCM and DMF recycled in-house via fractional distillation columns), optimized coupling stoichiometry (reducing coupling reagent consumption by 32%), and proprietary low-backpressure lyophilization lyophilizers, Thinheal delivers cost-efficiency advantages of 35%–50% compared to Western European or North American peptide custom houses.
Peptide manufacturing is transitioning from solvent-intensive batch synthesis to green, continuous, and hybrid paradigms. Thinheal's R&D center actively executes a structured technological advancement roadmap for SS-31 API industrialization.
High-yielding Fmoc solid-phase peptide synthesis utilizing specialized low-swelling resins, Oxyma Pure/DIC coupling chemistry, and mild cleavage protocols preventing Dmt degradation.
Transitioning coupling cycles to microfluidic packed-bed flow reactors, maintaining residence times under 3 minutes per residue, eliminating aggregation and truncated D-Arg deletions.
Coupling dipeptide fragments [Fmoc-D-Arg(Pbf)-Dmt-OH] with [H-Lys(Boc)-Phe-NH2] in solution phase to achieve multi-hundred-kilogram batch yields with reduced solvent footprints.
Replacing DMF/NMP with non-toxic Cyrene or 2-MeTHF; developing stable non-hygroscopic acetate, succinate, and phosphate salt forms for oral, transdermal, and ocular delivery.
Thinheal controls each lot through stringent analytical protocols including RP-HPLC, ESI-MS/MS, Residual Solvent Headspace GC, ICP-MS heavy metals, and LAL Bacterial Endotoxin assays.
| Quality Attribute Parameter | Standard R&D Research Grade | Thinheal Pharmaceutical & Clinical API Grade | Analytical Methodology |
|---|---|---|---|
| Chemical Identification | Conforms to Molecular Weight | Monoisotopic Mass: 639.80 ± 0.5 Da, MS/MS Sequence Confirmation | High-Resolution ESI-QTOF MS |
| Chromatographic Purity (HPLC) | ≥ 95.0% Area Normalized | ≥ 99.0% (Lot typical: 99.3% – 99.7%) | RP-HPLC (C18, TFA/MeCN Gradient, 214nm/280nm) |
| Single Major Known Impurity | Not strictly capped (≤ 2.0%) | ≤ 0.5% (Typically ≤ 0.15% per specific impurity) | Ultra-High-Performance LC-UV |
| Total Related Substances | ≤ 5.0% | ≤ 1.0% Max | Area Integration Exclusion of Blank |
| Net Peptide Content | Variable / Unreported | ≥ 80.0% – 88.0% w/w | Quantitative Amino Acid Analysis (AAA) |
| Counter-Ion Profiling | Crude Trifluoroacetate (TFA) | Acetate salt (≤ 10.0% w/w) or controlled low TFA (≤ 0.5% w/w) | Ion Chromatography (IC) |
| Residual Solvents (DMF, ACN, DCM) | Unmonitored | Complies with ICH Q3C (Class 2 & 3 Limits) | Headspace Gas Chromatography (HS-GC-FID) |
| Bacterial Endotoxins | Uncontrolled | < 5.0 EU/mg (or < 0.5 EU/mg for parenteral injectables) | Kinetic Turbidimetric / Chromogenic LAL |
Mitochondrial dysfunction has ascended to a premier focal point in modern therapeutic development, bridging rare disease orphan drug status with mainstream chronic indications.
Innovator trials led by Stealth BioTherapeutics for Barth syndrome (Phase 3 SPIBA-001/TAZPOWER) and Dry AMD with Geographic Atrophy have generated massive global clinical interest. With FDA Fast Track and Orphan Drug Designations established, global generics, 505(b)(2) developers, and formulation licensors are proactively positioning API pipelines to meet anticipated commercial demand.
Core composition-of-matter patents for early Szeto-Schiller tetrapeptides have expired or are nearing expiry across key territories, while subsequent secondary formulation and indication filings present well-defined design-around horizons. Progressive generic manufacturers in Asia and Europe are currently securing commercial DMF documentation to capitalize on immediate post-patent launches.
Beyond traditional ethical pharmaceuticals, clinical-grade SS-31 has gained substantial market share within wellness, longevity research institutes, and regenerative medicine networks in North America, the UAE, Australia, and East Asia. Sourcing procurement officers demand strictly traceable, synthetic purity to satisfy escalating consumer and institutional expectations.
Navigating global pharmaceutical regulatory expectations requires more than a simple Certificate of Analysis. Thinheal provides complete lifecycle CMC documentation and dedicated regional export support.
Thinheal supports customers filing IND, NDA, ANDA, and regional registrations. We provide comprehensive Chemistry, Manufacturing, and Controls (CMC) packages including detailed synthetic route descriptions, raw material specifications, analytical validation (ICH Q2(R1)), impurity characterization, and batch analysis data from consecutive commercial validation lots.
We welcome quality assurance and regulatory affairs teams from global pharmaceutical firms to conduct on-site facility audits in Hangzhou. Full access is granted to cleanroom suites, analytical instrument data logs (21 CFR Part 11 compliant chromatography software), water-for-injection systems, and quality management standard operating procedures.
Peptide APIs are sensitive to thermal excursions and moisture absorption. Thinheal guarantees cold-chain integrity from our warehouse to your receiving dock via temperature-monitored vacuum insulated shippers with dry ice or phase-change packs (-20°C / 2–8°C). Dedicated export desks coordinate customs clearances in the US, EU, CIS, and Asia-Pacific.
Critical technical, regulatory, and commercial questions answered for pharmaceutical procurement managers, formulation heads, and contract research leaders.
Explore our extensive line of generic APIs, metabolic incretins, and custom therapeutic peptides manufactured in Hangzhou.
Whether you are executing early preclinical pharmacodynamics or securing multi-kilogram commercial contracts, our Hangzhou engineering desk is prepared to deliver audited quality data, competitive volume pricing, and custom route development.
Thin